Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization

H. V. Naina, R. K. Pruthi, D. J. Inwards, D. Dingli, M. R. Litzow, S. M. Ansell, H. J. William, A. Dispenzieri, F. K. Buadi, M. A. Elliott, D. A. Gastineau, M. A. Gertz, S. R. Hayman, P. B. Johnston, M. Q. Lacy, I. N. Micallef, L. F. Porrata, S. Kumar

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The use of erythropoietic agents has been associated with an increased risk of venous thromboembolic events (VTEs), especially in patients with underlying malignancies. However, it is not known whether there is an increased risk of VTE associated with granulocyte growth factors. We reviewed 621 patients undergoing PBSC mobilization using granulocyte growth factors, alone or in combination with CY. Patients with a diagnosis of AL amyloidosis (AL: 114; 18%), multiple myeloma (MM: 278; 44%) Hodgkin lymphoma (HL: 20; 3%) or non-Hodgkin lymphoma (NHL: 209; 33%) were included. Symptomatic VTE occurred in six (0.97%) patients: two AL, two MM and two NHL. Of the six patients, two had pulmonary embolism, one developed deep vein thrombosis and three developed symptomatic catheter related thrombosis. Two patients with AL had heparin-induced thrombocytopenia and thrombosis. We found a low incidence of VTE among patients undergoing PBSC mobilization.

Original languageEnglish (US)
Pages (from-to)291-293
Number of pages3
JournalBone Marrow Transplantation
Volume46
Issue number2
DOIs
StatePublished - Feb 2011

Fingerprint

Intercellular Signaling Peptides and Proteins
Granulocytes
Thrombosis
Amyloidosis
Multiple Myeloma
Hodgkin Disease
Pulmonary Embolism
Venous Thrombosis
Thrombocytopenia
Non-Hodgkin's Lymphoma
Heparin
Catheters
Incidence
Neoplasms

Keywords

  • G-CSF
  • stem cell mobilization
  • venous thrombosis

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Naina, H. V., Pruthi, R. K., Inwards, D. J., Dingli, D., Litzow, M. R., Ansell, S. M., ... Kumar, S. (2011). Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization. Bone Marrow Transplantation, 46(2), 291-293. https://doi.org/10.1038/bmt.2010.106

Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization. / Naina, H. V.; Pruthi, R. K.; Inwards, D. J.; Dingli, D.; Litzow, M. R.; Ansell, S. M.; William, H. J.; Dispenzieri, A.; Buadi, F. K.; Elliott, M. A.; Gastineau, D. A.; Gertz, M. A.; Hayman, S. R.; Johnston, P. B.; Lacy, M. Q.; Micallef, I. N.; Porrata, L. F.; Kumar, S.

In: Bone Marrow Transplantation, Vol. 46, No. 2, 02.2011, p. 291-293.

Research output: Contribution to journalArticle

Naina, HV, Pruthi, RK, Inwards, DJ, Dingli, D, Litzow, MR, Ansell, SM, William, HJ, Dispenzieri, A, Buadi, FK, Elliott, MA, Gastineau, DA, Gertz, MA, Hayman, SR, Johnston, PB, Lacy, MQ, Micallef, IN, Porrata, LF & Kumar, S 2011, 'Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization', Bone Marrow Transplantation, vol. 46, no. 2, pp. 291-293. https://doi.org/10.1038/bmt.2010.106
Naina, H. V. ; Pruthi, R. K. ; Inwards, D. J. ; Dingli, D. ; Litzow, M. R. ; Ansell, S. M. ; William, H. J. ; Dispenzieri, A. ; Buadi, F. K. ; Elliott, M. A. ; Gastineau, D. A. ; Gertz, M. A. ; Hayman, S. R. ; Johnston, P. B. ; Lacy, M. Q. ; Micallef, I. N. ; Porrata, L. F. ; Kumar, S. / Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization. In: Bone Marrow Transplantation. 2011 ; Vol. 46, No. 2. pp. 291-293.
@article{040d5e26aa914c0aa45645f996f12f8f,
title = "Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization",
abstract = "The use of erythropoietic agents has been associated with an increased risk of venous thromboembolic events (VTEs), especially in patients with underlying malignancies. However, it is not known whether there is an increased risk of VTE associated with granulocyte growth factors. We reviewed 621 patients undergoing PBSC mobilization using granulocyte growth factors, alone or in combination with CY. Patients with a diagnosis of AL amyloidosis (AL: 114; 18{\%}), multiple myeloma (MM: 278; 44{\%}) Hodgkin lymphoma (HL: 20; 3{\%}) or non-Hodgkin lymphoma (NHL: 209; 33{\%}) were included. Symptomatic VTE occurred in six (0.97{\%}) patients: two AL, two MM and two NHL. Of the six patients, two had pulmonary embolism, one developed deep vein thrombosis and three developed symptomatic catheter related thrombosis. Two patients with AL had heparin-induced thrombocytopenia and thrombosis. We found a low incidence of VTE among patients undergoing PBSC mobilization.",
keywords = "G-CSF, stem cell mobilization, venous thrombosis",
author = "Naina, {H. V.} and Pruthi, {R. K.} and Inwards, {D. J.} and D. Dingli and Litzow, {M. R.} and Ansell, {S. M.} and William, {H. J.} and A. Dispenzieri and Buadi, {F. K.} and Elliott, {M. A.} and Gastineau, {D. A.} and Gertz, {M. A.} and Hayman, {S. R.} and Johnston, {P. B.} and Lacy, {M. Q.} and Micallef, {I. N.} and Porrata, {L. F.} and S. Kumar",
year = "2011",
month = "2",
doi = "10.1038/bmt.2010.106",
language = "English (US)",
volume = "46",
pages = "291--293",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization

AU - Naina, H. V.

AU - Pruthi, R. K.

AU - Inwards, D. J.

AU - Dingli, D.

AU - Litzow, M. R.

AU - Ansell, S. M.

AU - William, H. J.

AU - Dispenzieri, A.

AU - Buadi, F. K.

AU - Elliott, M. A.

AU - Gastineau, D. A.

AU - Gertz, M. A.

AU - Hayman, S. R.

AU - Johnston, P. B.

AU - Lacy, M. Q.

AU - Micallef, I. N.

AU - Porrata, L. F.

AU - Kumar, S.

PY - 2011/2

Y1 - 2011/2

N2 - The use of erythropoietic agents has been associated with an increased risk of venous thromboembolic events (VTEs), especially in patients with underlying malignancies. However, it is not known whether there is an increased risk of VTE associated with granulocyte growth factors. We reviewed 621 patients undergoing PBSC mobilization using granulocyte growth factors, alone or in combination with CY. Patients with a diagnosis of AL amyloidosis (AL: 114; 18%), multiple myeloma (MM: 278; 44%) Hodgkin lymphoma (HL: 20; 3%) or non-Hodgkin lymphoma (NHL: 209; 33%) were included. Symptomatic VTE occurred in six (0.97%) patients: two AL, two MM and two NHL. Of the six patients, two had pulmonary embolism, one developed deep vein thrombosis and three developed symptomatic catheter related thrombosis. Two patients with AL had heparin-induced thrombocytopenia and thrombosis. We found a low incidence of VTE among patients undergoing PBSC mobilization.

AB - The use of erythropoietic agents has been associated with an increased risk of venous thromboembolic events (VTEs), especially in patients with underlying malignancies. However, it is not known whether there is an increased risk of VTE associated with granulocyte growth factors. We reviewed 621 patients undergoing PBSC mobilization using granulocyte growth factors, alone or in combination with CY. Patients with a diagnosis of AL amyloidosis (AL: 114; 18%), multiple myeloma (MM: 278; 44%) Hodgkin lymphoma (HL: 20; 3%) or non-Hodgkin lymphoma (NHL: 209; 33%) were included. Symptomatic VTE occurred in six (0.97%) patients: two AL, two MM and two NHL. Of the six patients, two had pulmonary embolism, one developed deep vein thrombosis and three developed symptomatic catheter related thrombosis. Two patients with AL had heparin-induced thrombocytopenia and thrombosis. We found a low incidence of VTE among patients undergoing PBSC mobilization.

KW - G-CSF

KW - stem cell mobilization

KW - venous thrombosis

UR - http://www.scopus.com/inward/record.url?scp=79951678628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951678628&partnerID=8YFLogxK

U2 - 10.1038/bmt.2010.106

DO - 10.1038/bmt.2010.106

M3 - Article

VL - 46

SP - 291

EP - 293

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 2

ER -